electroCore Expands Intellectual Property Portfolio With Two New Patents, "No. 11,944,815" And "No. 11,944,807"
$ECOR
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue notifications from the United States Patent and Trademark Office (USPTO). The two patents were issued on April 2, 2024, and relate to electroCore's non-invasive vagus nerve stimulation (nVNS) technology:
- US Patent No. 11,944,815 entitled "Non-Invasive Nerve Stimulation with Mobile Device" generally relates to a system for transcutaneously stimulating a nerve in a patient that includes a downloadable software application configured to wirelessly transmit a therapy regimen to a stimulator. The therapy regimen comprises generating an electrical signal for approximately 5 minutes to 30 minutes.
- US Patent No. 11,944,807 entitled "Vagal Nerve Stimulation for Treating Central Nervous System Disorders" generally relates to methods for treating central nervous disorders, such as PTSD, fibromyalgia, anxiety and TBI by applying electrical impulses to the vagus nerve according to a stimulation protocol that includes at least two doses each day. The electrical impulses are bursts of 2 to 20 sinusoidal pulses.